Crispr Therapeutics AG vs Packaging Corporation of America — how do they compare? Crispr Therapeutics AG trades at $53.2 (market cap $4.88B), while Packaging Corporation of America trades at $229.06 (market cap $20.49B). The key difference: Packaging Corporation of America is far larger — about 4.2× Crispr Therapeutics AG's market cap, and Packaging Corporation of America pays a 2.61% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Packaging Corporation of America for 45 Days on average.
| CRSP | PKG | |
|---|---|---|
Market Cap | $4.88B | $20.49B |
Volume | 2,861,747 | 493,499 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $257.43 |
52-Week Low | $44.34 | $191.68 |
Typical Hold Time | 77 Days | 45 Days |
Enterprise Value | $3.30B | $24.30B |
Dividend Yield | — | 2.61% |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Packaging Corporation of America (PKG) trades at $229.06, up 0.8% on the day, amid a bearish technical signal and mixed earnings performance. The stock shows strong profitability with a 7.26% net income margin and 14.79% ROE, though 2026 profit margins are projected to decline. Recent news highlights institutional buying and a steady dividend, while analyst consensus is a $272.43 price target with a 'Hold' bias.
PKG offers value through its dividend and stable business model but faces headwinds from cost pressures and negative cash flow trends. The stock's near-term performance hinges on Q3 2026 earnings results, with risks including margin compression and economic sensitivity. Upside exists if the company beats expectations and manages costs effectively.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →